Investor “Pharma Bro” Martin Shkreli said on X that Iovance Biotherapeutics is a “pretty attractive long idea.” Shkreli also discussed the company on his YouTube channel.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
- Iovance Biotherapeutics price target lowered to $24 from $26 at Baird
- Iovance Biotherapeutics reports Q2 EPS (34c), consensus (35c)
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024